Detalhe da pesquisa
1.
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
BMC Cancer
; 20(1): 492, 2020 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32487038